Engin Kaya
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Engin Kaya has a total of 85 co-authors. Here are the top co-authors by number of shared publications:
- Sercan Yilmaz
Department of Urology, Gulhane Training and Research Hospital, Ankara, Turkey
17 shared publications - Eymen Gazel
Acıbadem University Ankara Hospital, Department of Urology, Ankara, Turkey
12 shared publications - Lutfi Tunc
Department of Urology, Gazi University School of Medicine, Ankara, Turkey
12 shared publications - Serdar Yalçın
Department of Urology, Gülhane Training and Research Hospital, Health Sciences University, Ankara, Turkey
12 shared publications - Halil Cagri Aybal
Kahramankazan Hamdi Eris State Hospital, Department of Urology, Ankara, Turkey
11 shared publications - Turgay Ebiloğlu
Department of Urology, University of Health Sciences, Gulhane Research and Training Hospital, Emrah Mahallesi, General Tevfik Saglam Caddesi, Etlik, Ankara, Turkey
8 shared publications
Latest Publications
- 29 November 2024
- Published by Springer Nature in World Journal of Urology
- Vol. 43 (1) , 1-7
Endoscopic holmium laser harvesting of bladder mucosal graft for urethroplasty: retrospective analysis of single center preliminary results
Purpose Urethral stricture disease (USD) incidence is estimated to be as high as 0.6–1.2%. In 2022, it was published that the bladder mucosal graft to be used in urethroplasty can be obtained endoscopically with a holmium laser. We aimed to present our single center graft urethroplasty results obtained with the endoscopic holmium laser harvesting of bladder mucosal graft technique. Methods We retrospectively reviewed the results of patients who underwent bladder mucosal graft (BlMG) urethroplasty by single surgeon at our center hospital between December 2022 and May 2023. Results A total of 14 patients underwent BlMG urethroplasty surgery. Of them 8 were male and 6 were female patients. The mean patient age was 53 (range 26–76) years. The mean length of stricture was 4,35 (range 1–11) cm. The maximum postoperative flow rate was < 10 ml/sec in three of the 14 patients. Conclusion To our knowledge this is the first study investigating the preliminary results of substitution urethroplasties that is performed with bladder mucosal grafts harvested with laser energy via transurethral (endoscopic) route. Though more work is needed to better understand its current role in complex urethral reconstruction, our patient cohort will be a niche for further studies.
- 29 November 2024
- Published by Springer Nature in World Journal of Urology
- Vol. 43 (1) , 1-7
Endoscopic holmium laser harvesting of bladder mucosal graft for urethroplasty: retrospective analysis of single center preliminary results
Purpose Urethral stricture disease (USD) incidence is estimated to be as high as 0.6–1.2%. In 2022, it was published that the bladder mucosal graft to be used in urethroplasty can be obtained endoscopically with a holmium laser. We aimed to present our single center graft urethroplasty results obtained with the endoscopic holmium laser harvesting of bladder mucosal graft technique. Methods We retrospectively reviewed the results of patients who underwent bladder mucosal graft (BlMG) urethroplasty by single surgeon at our center hospital between December 2022 and May 2023. Results A total of 14 patients underwent BlMG urethroplasty surgery. Of them 8 were male and 6 were female patients. The mean patient age was 53 (range 26–76) years. The mean length of stricture was 4,35 (range 1–11) cm. The maximum postoperative flow rate was < 10 ml/sec in three of the 14 patients. Conclusion To our knowledge this is the first study investigating the preliminary results of substitution urethroplasties that is performed with bladder mucosal grafts harvested with laser energy via transurethral (endoscopic) route. Though more work is needed to better understand its current role in complex urethral reconstruction, our patient cohort will be a niche for further studies.
- 21 February 2022
- Published by Pera Yayıncılık Hizmetleri in Yeni Üroloji Dergisi
- Vol. 17 (1) , 6-13
Hawk® JAWS versus Lumenis® VersaCut prostate morcellation devices: A comparative study and comprehensive literature review
Objective: Although morcellation is a standard procedure of Holmium Laser Enucleation of the Prostate (HoLEP), studies on the morcellators used are limited in number. We aimed to compare two different tissue morcellators used in HoLEP, which have similar objectives but differences in efficiency and safety in working principles. Material and Methods: The data of 130 patients who underwent HoLEP between December 2018 and December 2019 were retrospectively reviewed. Sixty-five patients received Lumenis® Versacut (Lumenis Inc., Santa Clara, CA, USA) morcellator and 65 patients received Hawk® JAWS (Hawk, Minitech Co., China) morcellator after enucleation were included in the study. The efficiency of morcellation (g/min), morcellation time (min), total operation time (min), enucleation time (min), enucleated tissue weight (g), the efficiency of enucleation, densities of the removed prostate tissues, perioperative complications associated with the use of a morcellator were recorded perioperatively. Results: There was no significant difference in total operation time (min), enucleation time (min), enucleated tissue weight (g), and efficiency of enucleation (g/min) efficiency of morcellation, morcellation time (min) between the two groups. Bladder mucosal damage occurred in 3 patients (4%) in the Versacut group, while mucosal bladder damage was not observed in any patient in the Hawk® JAWS group (p = 0.08). Conclusion: Hawk® JAWS and Lumenis® VersaCut morcellators were comparable in their efficiency and safety. Keywords: Hawk, HoLEP, morcellation, morcellator, Versacut.
- 21 February 2022
- Published by Pera Yayıncılık Hizmetleri in Yeni Üroloji Dergisi
- Vol. 17 (1) , 6-13
Hawk® JAWS versus Lumenis® VersaCut prostate morcellation devices: A comparative study and comprehensive literature review
Objective: Although morcellation is a standard procedure of Holmium Laser Enucleation of the Prostate (HoLEP), studies on the morcellators used are limited in number. We aimed to compare two different tissue morcellators used in HoLEP, which have similar objectives but differences in efficiency and safety in working principles. Material and Methods: The data of 130 patients who underwent HoLEP between December 2018 and December 2019 were retrospectively reviewed. Sixty-five patients received Lumenis® Versacut (Lumenis Inc., Santa Clara, CA, USA) morcellator and 65 patients received Hawk® JAWS (Hawk, Minitech Co., China) morcellator after enucleation were included in the study. The efficiency of morcellation (g/min), morcellation time (min), total operation time (min), enucleation time (min), enucleated tissue weight (g), the efficiency of enucleation, densities of the removed prostate tissues, perioperative complications associated with the use of a morcellator were recorded perioperatively. Results: There was no significant difference in total operation time (min), enucleation time (min), enucleated tissue weight (g), and efficiency of enucleation (g/min) efficiency of morcellation, morcellation time (min) between the two groups. Bladder mucosal damage occurred in 3 patients (4%) in the Versacut group, while mucosal bladder damage was not observed in any patient in the Hawk® JAWS group (p = 0.08). Conclusion: Hawk® JAWS and Lumenis® VersaCut morcellators were comparable in their efficiency and safety. Keywords: Hawk, HoLEP, morcellation, morcellator, Versacut.
- 1 December 2021
- Published by Galenos Yayinevi in Journal of Urological Surgery
- Vol. 8 (4) , 261-265
Sacral Neuromodulation Treatment for Non-neurogenic Urological Disorders: Experience of a Single Center in Turkey
- 1 December 2021
- Published by Galenos Yayinevi in Journal of Urological Surgery
- Vol. 8 (4) , 261-265
Sacral Neuromodulation Treatment for Non-neurogenic Urological Disorders: Experience of a Single Center in Turkey
- Open Access
- 1 July 2021
- Published by FapUNIFESP (SciELO) in Revista da Associação Médica Brasileira
- Vol. 67 (7) , 958-965
The timing of micro-TESE: what is the ideal age for male and female partner to bring a child to home?
OBJECTIVE: The aim of this study was to analyze the results of microsurgical testicular sperm extraction (micro-TESE) and investigate the potential factors that may affect the successful sperm retrieval and timing of micro-TESE. METHODS: A total of 56 patients with nonobstructive azoospermia (NOA) who underwent micro-TESE procedure between January 2017 and December 2019 were retrospectively analyzed. The patient age, marriage duration, infertility duration, smoking, chronic illness, varicocele status, previous scrotal surgeries, and the presence of genetic disease were noted by an urologist for all patients. RESULTS: The mean age of patients was 33.28 +/- 4.4 (22-44) years. Our total sperm-retrieval rate was 55.4% (n:31). Sixteen (28.6%) pregnancies were achieved and 15 (26.8%) healthy live births could be managed. Only the marriage duration (p=0.016) and infertility duration (p=0.015) were detected to be the significant factors to manage successful sperm retrieval. Men with NOA younger than 35.2 years and having a female partner younger than 36.9 years seemed to have the best chance to have a living healthy baby. CONCLUSIONS: The fertility decreased by both male and female age and for men with NOA. The early visit to doctor seemed to have positive effect.
- 1 July 2021
- Published by FapUNIFESP (SciELO) in Revista da Associação Médica Brasileira
- Vol. 67 (7) , 958-965
Open AccessThe timing of micro-TESE: what is the ideal age for male and female partner to bring a child to home?
OBJECTIVE: The aim of this study was to analyze the results of microsurgical testicular sperm extraction (micro-TESE) and investigate the potential factors that may affect the successful sperm retrieval and timing of micro-TESE. METHODS: A total of 56 patients with nonobstructive azoospermia (NOA) who underwent micro-TESE procedure between January 2017 and December 2019 were retrospectively analyzed. The patient age, marriage duration, infertility duration, smoking, chronic illness, varicocele status, previous scrotal surgeries, and the presence of genetic disease were noted by an urologist for all patients. RESULTS: The mean age of patients was 33.28 +/- 4.4 (22-44) years. Our total sperm-retrieval rate was 55.4% (n:31). Sixteen (28.6%) pregnancies were achieved and 15 (26.8%) healthy live births could be managed. Only the marriage duration (p=0.016) and infertility duration (p=0.015) were detected to be the significant factors to manage successful sperm retrieval. Men with NOA younger than 35.2 years and having a female partner younger than 36.9 years seemed to have the best chance to have a living healthy baby. CONCLUSIONS: The fertility decreased by both male and female age and for men with NOA. The early visit to doctor seemed to have positive effect.
- Open Access
- 20 June 2021
- Published by Pera Yayıncılık Hizmetleri in Yeni Üroloji Dergisi
- Vol. 16 (16-2) , 140-147
Single center results of magnetic resonance imaging ultrasound guided fusion prostate biopsy obtained patients
Objective: We aimed to evaluate magnetic resonance imaging-ultrasound guided fusion prostate biopsy (MRI- US FPBx) results from a single center and to compare with current literature. Material and Methods: Between January 2016 and July 2019, MRI-US FPBx pathological and imaging results of 358 men were retrospectively analyzed. PI-RADS scores were determined as 3, 4 and 5 in 222 (62%), 107 (29.8%) and 29 (8.1%) patients, respectively. Totally 454 lesions were underwent MRI-US FPBx. 303 (66.7%) lesions were scored as PI-RADS 3, 120 (26.4%) lesions were scored as PI-RADS 4 and 31 (6.8%) lesions were scored as PI-RADS 5. 315 (69.3%) of lesions were in peripheral zone, 26 (5.7%) were in central zone, 111 (24.4%) were in transitional zone and 2 of them were in anterior fibromuscular stroma. Results: Overall prostate cancer detection rate was 36.3%. Concerning detection rates, MRI-US FPBx alone and transrectal ultrasonography guided prostate biopsy (TRUS-Bx) alone were 27.6% and 26.5%, respectively. Cancer detection rate only through MRI-US FPBx PIRADS-3 and PI-RADS 4&5 were 6.9% and 20.6%, respectively. Clinically significant prostate cancer (csPCa) rates were evaluated and csPCa to overall prostate cancer (PCa) rates for TRUS-Bx, MRI-US FPBx and combined techniques were 16.8%, 35.4% and 39.2%, respectively. Results of 11 patients were evaluated as benign. Conclusion: MRI-US FPBx significantly increases success rate of prostate biopsy procedure. Regarding current MRI technology, it is not appropriate to consider MRI-US FPBx as a stand-alone biopsy option without concomitant with TRUS-Bx. Keywords: prostate cancer; biopsy; MRI; fusion
- 20 June 2021
- Published by Pera Yayıncılık Hizmetleri in Yeni Üroloji Dergisi
- Vol. 16 (16-2) , 140-147
Open AccessSingle center results of magnetic resonance imaging ultrasound guided fusion prostate biopsy obtained patients
Objective: We aimed to evaluate magnetic resonance imaging-ultrasound guided fusion prostate biopsy (MRI- US FPBx) results from a single center and to compare with current literature. Material and Methods: Between January 2016 and July 2019, MRI-US FPBx pathological and imaging results of 358 men were retrospectively analyzed. PI-RADS scores were determined as 3, 4 and 5 in 222 (62%), 107 (29.8%) and 29 (8.1%) patients, respectively. Totally 454 lesions were underwent MRI-US FPBx. 303 (66.7%) lesions were scored as PI-RADS 3, 120 (26.4%) lesions were scored as PI-RADS 4 and 31 (6.8%) lesions were scored as PI-RADS 5. 315 (69.3%) of lesions were in peripheral zone, 26 (5.7%) were in central zone, 111 (24.4%) were in transitional zone and 2 of them were in anterior fibromuscular stroma. Results: Overall prostate cancer detection rate was 36.3%. Concerning detection rates, MRI-US FPBx alone and transrectal ultrasonography guided prostate biopsy (TRUS-Bx) alone were 27.6% and 26.5%, respectively. Cancer detection rate only through MRI-US FPBx PIRADS-3 and PI-RADS 4&5 were 6.9% and 20.6%, respectively. Clinically significant prostate cancer (csPCa) rates were evaluated and csPCa to overall prostate cancer (PCa) rates for TRUS-Bx, MRI-US FPBx and combined techniques were 16.8%, 35.4% and 39.2%, respectively. Results of 11 patients were evaluated as benign. Conclusion: MRI-US FPBx significantly increases success rate of prostate biopsy procedure. Regarding current MRI technology, it is not appropriate to consider MRI-US FPBx as a stand-alone biopsy option without concomitant with TRUS-Bx. Keywords: prostate cancer; biopsy; MRI; fusion
- Open Access
- 20 June 2021
- Published by Pera Yayıncılık Hizmetleri in Yeni Üroloji Dergisi
- Vol. 16 (16-2) , 184-189
Basic factors predicting prostate cancer in Prostate Imaging Reporting and Data System-3 lesions
Objective: We aimed to investigate the role of the digital rectal examination, PSA density, regional location of the lesion and prostate size in predicting prostate cancer in Prostate Imaging and Data Reporting System (PI-RADS)-3 lesions. Material and Methods: A total of 236 patients with multiparametric MRI performed for clinical suspicion of prostate cancer and reported PI-RADS-3 enrolled between January 2016 and July 2019 in this retrospective study. The datas were extracted from the hospital’s electronic records, patient files and outpatient clinic records. Multiparametric MRI was performed patients to whom have elevated PSA level and/or suspicious digital rectal examination. Patients diagnosed with and without prostate cancer were compared in terms of age, PSA, PSA density, prostate size, pathological results, lesion localization and DRE findings. Results: One hundred thirty- independent predictor seven patients with an initial score of PI-RADS-3 were subjected to further analysis. Prostat cancer detection rate in overall and clinically significant prostate cancer detection rate was 26.2% and 4.3%, respectively. There was a significant difference regarding DRE findings (p=0.001) and PZ location of the lesion (p=0.005) between PCa and no PCa groups. Digital rectal examination (p=0.001) was an independent predictor of prostate cancer in multivariate logistic regression analysis. Conclusion: Digital rectal examination is a practical and important parameter in clarifying the suspicion of prostate cancer in PI-RADS-3 lesions. Keywords: prostatic neoplasms, digital rectal examination, multiparametric magnetic resonance imaging, image guided biopsy
- 20 June 2021
- Published by Pera Yayıncılık Hizmetleri in Yeni Üroloji Dergisi
- Vol. 16 (16-2) , 184-189
Open AccessBasic factors predicting prostate cancer in Prostate Imaging Reporting and Data System-3 lesions
Objective: We aimed to investigate the role of the digital rectal examination, PSA density, regional location of the lesion and prostate size in predicting prostate cancer in Prostate Imaging and Data Reporting System (PI-RADS)-3 lesions. Material and Methods: A total of 236 patients with multiparametric MRI performed for clinical suspicion of prostate cancer and reported PI-RADS-3 enrolled between January 2016 and July 2019 in this retrospective study. The datas were extracted from the hospital’s electronic records, patient files and outpatient clinic records. Multiparametric MRI was performed patients to whom have elevated PSA level and/or suspicious digital rectal examination. Patients diagnosed with and without prostate cancer were compared in terms of age, PSA, PSA density, prostate size, pathological results, lesion localization and DRE findings. Results: One hundred thirty- independent predictor seven patients with an initial score of PI-RADS-3 were subjected to further analysis. Prostat cancer detection rate in overall and clinically significant prostate cancer detection rate was 26.2% and 4.3%, respectively. There was a significant difference regarding DRE findings (p=0.001) and PZ location of the lesion (p=0.005) between PCa and no PCa groups. Digital rectal examination (p=0.001) was an independent predictor of prostate cancer in multivariate logistic regression analysis. Conclusion: Digital rectal examination is a practical and important parameter in clarifying the suspicion of prostate cancer in PI-RADS-3 lesions. Keywords: prostatic neoplasms, digital rectal examination, multiparametric magnetic resonance imaging, image guided biopsy
- 31 May 2021
- Published by Hindawi Limited in Andrologia
- Vol. 53 (8) , e14137
Is ‘Omega Sign’ anatomical endoscopic enucleation of the prostate technique reproducible?
We aimed to evaluate the learning curve of the surgically standardised ‘Omega Sign’ anatomical endoscopic enucleation (AEEP) of the prostate surgery technique for junior surgeons. This study is a retrospective comparison of cases that underwent AEEP by a mentor surgeon and three junior surgeons who have completed their learning curve. A video-based laser enucleation of the prostate assessment tool (LEAT) composed of 8 steps of the technique was used to assess a senior surgeon and junior surgeons’ surgical compatibility and consistency. The surgeon who defined Omega Sign technique was determined as group 1, and cases by three junior surgeons were identified as group 2. The end points were to assess the reproducibility and repeatability and operative post-operative outcomes of the technique. 55 patients’ videos were rated by five experienced endourologists. There was no significant difference in LEAT scores between the groups among all steps. The most symmetry was found in the 1st and 3rd steps. Inter-rater consistency was also high for each step, with no statistically significant difference between the evaluators. The standardised anatomical ‘Omega Sign’ technique is reproducible for the junior surgeons. The operative steps can be performed with high consistency, and the functional and perioperative outcomes are comparable with the senior surgeon.
- 31 May 2021
- Published by Hindawi Limited in Andrologia
- Vol. 53 (8) , e14137
Is ‘Omega Sign’ anatomical endoscopic enucleation of the prostate technique reproducible?
We aimed to evaluate the learning curve of the surgically standardised ‘Omega Sign’ anatomical endoscopic enucleation (AEEP) of the prostate surgery technique for junior surgeons. This study is a retrospective comparison of cases that underwent AEEP by a mentor surgeon and three junior surgeons who have completed their learning curve. A video-based laser enucleation of the prostate assessment tool (LEAT) composed of 8 steps of the technique was used to assess a senior surgeon and junior surgeons’ surgical compatibility and consistency. The surgeon who defined Omega Sign technique was determined as group 1, and cases by three junior surgeons were identified as group 2. The end points were to assess the reproducibility and repeatability and operative post-operative outcomes of the technique. 55 patients’ videos were rated by five experienced endourologists. There was no significant difference in LEAT scores between the groups among all steps. The most symmetry was found in the 1st and 3rd steps. Inter-rater consistency was also high for each step, with no statistically significant difference between the evaluators. The standardised anatomical ‘Omega Sign’ technique is reproducible for the junior surgeons. The operative steps can be performed with high consistency, and the functional and perioperative outcomes are comparable with the senior surgeon.
- Open Access
- 24 May 2021
- Published by Wiley in Andrologia
- Vol. 53 (8) , e14125
Laser enucleation for prostates larger than 100 mL: Comparison of HoLEP and ThuLEP
Recently, with the advancements in laser technology, Holmium laser enucleation of the prostate (HoLEP) and Thulium laser enucleation of the prostate (ThuLEP) have come to the fore in the surgical treatment of benign prostatic hyperplasia (BPH). We aimed to evaluate and compare the outcomes of HoLEP and ThuLEP in patients with >100 ml prostate volume. Patients who underwent HoLEP and ThuLEP between July 2017 and March 2020 were reviewed retrospectively. The patients were divided into two groups as HoLEP (Group 1, n = 121) and ThuLEP (Group 2, n = 104). Perioperative parameters, functional outcomes, continence status, intra and post-operative complications were compared between groups in the post-operative 1st and 6th month. No significant difference was found in terms of total laser energy (TLE), morcellation efficiency (ME), enucleated tissue weight (ETW), complication rates (CR) and continence status of patients between both groups (p > .05). In favour of ThuLEP group, there were statistically significant differences regarding total operation time (TOT), laser efficiency (LE), enucleation time (ET) and enucleation efficiency (EE) between groups (p ≤ .05). HoLEP and ThuLEP can be used safely and effectively in prostates larger than 100 ml.
- 24 May 2021
- Published by Wiley in Andrologia
- Vol. 53 (8) , e14125
Open AccessLaser enucleation for prostates larger than 100 mL: Comparison of HoLEP and ThuLEP
Recently, with the advancements in laser technology, Holmium laser enucleation of the prostate (HoLEP) and Thulium laser enucleation of the prostate (ThuLEP) have come to the fore in the surgical treatment of benign prostatic hyperplasia (BPH). We aimed to evaluate and compare the outcomes of HoLEP and ThuLEP in patients with >100 ml prostate volume. Patients who underwent HoLEP and ThuLEP between July 2017 and March 2020 were reviewed retrospectively. The patients were divided into two groups as HoLEP (Group 1, n = 121) and ThuLEP (Group 2, n = 104). Perioperative parameters, functional outcomes, continence status, intra and post-operative complications were compared between groups in the post-operative 1st and 6th month. No significant difference was found in terms of total laser energy (TLE), morcellation efficiency (ME), enucleated tissue weight (ETW), complication rates (CR) and continence status of patients between both groups (p > .05). In favour of ThuLEP group, there were statistically significant differences regarding total operation time (TOT), laser efficiency (LE), enucleation time (ET) and enucleation efficiency (EE) between groups (p ≤ .05). HoLEP and ThuLEP can be used safely and effectively in prostates larger than 100 ml.
- Open Access
- 1 April 2021
- Published by FapUNIFESP (SciELO) in Revista da Associação Médica Brasileira
- Vol. 67 (4) , 577-584
Examination of clinical data and semen analysis results of patients undergoing orchiectomy for testicular tumor
OBJECTIVE: Testicular tumor constitutes 1% of male neoplasms. Infertility can be determined in patients with testicular tumors before orchiectomy due to the deterioration of spermatogenesis. The aim of this study was to show the clinical, radiological, and pathological characteristics and spermiogram results of patients with testicular tumor and their relationship with each other. METHODS: The data of patients who underwent orchiectomy due to testicular tumor between 2016 and 2019 were reviewed retrospectively. These data included sociodemographic data of the patients, pretreatment spermiogram characteristics, level of serum tumor markers, characteristics of the ultrasonography, type of orchiectomy, and histopathological examination. RESULTS: This study included 53 male patients, with a mean age of 33.51 +/- 12.86 years. The mean levels of all tumor markers were above the reference levels. The mean tumor size was 34.68 +/- 23.32 mm. Multiple localizations and microlithiasis were detected in 11.3 and 13.2% of the tumors, respectively. The most common masses were hypoechoic (n=37; 69.8%) and hypervascular (n=47; 81%). Spermiogram and cryopreservation were performed in 29 (54.7%) of 53 patients preoperatively. The mean sperm concentration before orchiectomy was 24.21x10(6)/mL and group A sperm motility 0.79%, group B sperm motility 39.10%, group C sperm motility 9.83%, and group D sperm motility 22.69% in testicular tumors. CONCLUSION: Spermatogenesis adversely affected before the treatment due to local and systemic effects of testicular cancer. Fertility expectations can be increased in the subsequent years by semen analysis and referral to cryopreservation.
- 1 April 2021
- Published by FapUNIFESP (SciELO) in Revista da Associação Médica Brasileira
- Vol. 67 (4) , 577-584
Open AccessExamination of clinical data and semen analysis results of patients undergoing orchiectomy for testicular tumor
OBJECTIVE: Testicular tumor constitutes 1% of male neoplasms. Infertility can be determined in patients with testicular tumors before orchiectomy due to the deterioration of spermatogenesis. The aim of this study was to show the clinical, radiological, and pathological characteristics and spermiogram results of patients with testicular tumor and their relationship with each other. METHODS: The data of patients who underwent orchiectomy due to testicular tumor between 2016 and 2019 were reviewed retrospectively. These data included sociodemographic data of the patients, pretreatment spermiogram characteristics, level of serum tumor markers, characteristics of the ultrasonography, type of orchiectomy, and histopathological examination. RESULTS: This study included 53 male patients, with a mean age of 33.51 +/- 12.86 years. The mean levels of all tumor markers were above the reference levels. The mean tumor size was 34.68 +/- 23.32 mm. Multiple localizations and microlithiasis were detected in 11.3 and 13.2% of the tumors, respectively. The most common masses were hypoechoic (n=37; 69.8%) and hypervascular (n=47; 81%). Spermiogram and cryopreservation were performed in 29 (54.7%) of 53 patients preoperatively. The mean sperm concentration before orchiectomy was 24.21x10(6)/mL and group A sperm motility 0.79%, group B sperm motility 39.10%, group C sperm motility 9.83%, and group D sperm motility 22.69% in testicular tumors. CONCLUSION: Spermatogenesis adversely affected before the treatment due to local and systemic effects of testicular cancer. Fertility expectations can be increased in the subsequent years by semen analysis and referral to cryopreservation.
- 13 November 2020
- Published by Springer Nature in World Journal of Urology
- Vol. 39 (7) , 2605-2611
HoLEP after prostate biopsy: does it have any impact?
Purpose Holmium laser enucleation of the prostate (HoLEP) has recently become the recommended treatment for prostate in all sizes in benign prostate hyperplasia surgery. A recent prostate biopsy performed prior to the HoLEP procedure can make surgeons concerned about the surgery. We aimed to investigate the per- and postoperative outcomes of the HoLEP procedure in patients who underwent prostate biopsy and to evaluate the most appropriate surgery time after biopsy. Methods The data of 160 patients who underwent HoLEP by a single surgeon between March 2017 and December 2019 were retrospectively reviewed. The patients were divided into two groups, Group 1 consisted of 80 patients without prostate biopsy and Group 2 consisted of 80 patients with prior prostate biopsy. All HOLEP procedures in group 2 were performed at least 2 weeks following biopsy. Per- and postoperative outcomes, complications were evaluated. Results No significant differences were found between groups in terms of by enucleation time, efficiency of laser, efficiency of enucleation, hospitalization time, and catheterization removal time. Only morcellation time was shorter in biopsy naïve patients. There were no statistical differences in postoperative outcomes. Previous prostate biopsy did not affect the continence status in our study group. There were not any Clavien grade 4 or higher complications. Urinary tract infection was higher in early post-biopsy period, there was no difference among the groups. Conclusıon Our study confirms that HoLEP is a safe and efficient surgical procedure for the patients with prior prostate biopsy. We believe that it can be safely performed 2nd week following prostate biopsy.
- 13 November 2020
- Published by Springer Nature in World Journal of Urology
- Vol. 39 (7) , 2605-2611
HoLEP after prostate biopsy: does it have any impact?
Purpose Holmium laser enucleation of the prostate (HoLEP) has recently become the recommended treatment for prostate in all sizes in benign prostate hyperplasia surgery. A recent prostate biopsy performed prior to the HoLEP procedure can make surgeons concerned about the surgery. We aimed to investigate the per- and postoperative outcomes of the HoLEP procedure in patients who underwent prostate biopsy and to evaluate the most appropriate surgery time after biopsy. Methods The data of 160 patients who underwent HoLEP by a single surgeon between March 2017 and December 2019 were retrospectively reviewed. The patients were divided into two groups, Group 1 consisted of 80 patients without prostate biopsy and Group 2 consisted of 80 patients with prior prostate biopsy. All HOLEP procedures in group 2 were performed at least 2 weeks following biopsy. Per- and postoperative outcomes, complications were evaluated. Results No significant differences were found between groups in terms of by enucleation time, efficiency of laser, efficiency of enucleation, hospitalization time, and catheterization removal time. Only morcellation time was shorter in biopsy naïve patients. There were no statistical differences in postoperative outcomes. Previous prostate biopsy did not affect the continence status in our study group. There were not any Clavien grade 4 or higher complications. Urinary tract infection was higher in early post-biopsy period, there was no difference among the groups. Conclusıon Our study confirms that HoLEP is a safe and efficient surgical procedure for the patients with prior prostate biopsy. We believe that it can be safely performed 2nd week following prostate biopsy.